In response to the call for Public Private Partnership Projects (PPPP) launched in February 2010, the Indo Swiss Joint Research Programme (ISJRP) received three eligible applications. One of these was approved for funding. The success rate was 33%.
ISJRP Grant no. 11520.1
Development of methods and protocols for deep brain stimulation of amygdala to treat temporal lobe epilepsy and anxiety disorders
Main university partners
Dr. Ron Stoop & M.Ch. Roy Daniel, Centre for Psychiatric Neuroscience & Service de neurochirurgie, UNIL/CHUV, Lausanne
Dr. Srinivasa Babu, Christian Medical College, Vellore
Main business partners
Dr. Jean-Pierre Rosat, Aleva Neurotherapeutics SA, Renens-VD
Mr. Nandagopal Mannam, Alliance Biomedica Pvt Ltd
Project duration: 01.01.2011 – 31.12.2012
Funding from ISJRP (Swiss budget): CHF 386’436.00
Funding from businesses (Swiss budget): CHF 386’436.00
Project focus: Deep Brain Stimulation (DBS) involves the implantation of electrodes to therapeutically stimulate brain regions. It has demonstrated superior outcomes in Movement Disorders and is being studied for other indications like temporal lobe epilepsy (TLE) in the amygdala. This highly epileptogenic center is also related to anxiety and fear disorders. The project aims to study the use of deep brain stimulation in the treatment of these diseases using sophisticated new device technology.
Innovation & market impact: Currently there are few studies in animal models to determine efficiency of DBS for treatment of TLE. Our study will be aimed at developing new protocols towards validating the use of DBS in the treatment of TLE. Successful treatment in animal models will open new perspectives for validating similar treatment in human patients. Furthermore, all research conducted in animal models for epilepsy is potentially translatable to the study and treatment of other indications such as fear and anxiety disorders.
Business partners: The Swiss business partner, Aleva Neurotherapeutics, was founded on the principle of using innovative medical device technology to enable the treatment of new indications in neurological disorders. Furthermore, the Indian business partner has the clinical sales pipeline in order to exploit the new technology and make a convincing argument that neurosurgeons require these devices for the treatment of their patients.